Market Cap 807.38M
Revenue (ttm) 0.00
Net Income (ttm) -17.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 107,013
Avg Vol 171,026
Day's Range N/A - N/A
Shares Out 11.06M
Stochastic %K 34%
Beta -0.13
Analysts Strong Sell
Price Target $82.83

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 253 1461
Address:
125 Strafford Avenue, Suite 360, Wayne, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $71.45 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $14.49- $17.71 Scale out: $22.54-$28.98 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
TalkMarkets
TalkMarkets Oct. 22 at 9:42 AM
Markets Are Choppy, But This One Zone Could Tell Us What’s Next For The S&P 500 $SPX $GH $BABA $PVLA https://talkmarkets.com/content/stocks--equities/markets-are-choppy-but-this-one-zone-could-tell-us-whats-next-for-the-sp-500?post=529717&userid=166882
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 18 at 5:46 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $73.14 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $11.70- $14.30 Scale out: $18.20-$23.40 Can Easily Capture: 60% ROI Blended DTE: 210 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
dadamoni
dadamoni Oct. 15 at 11:56 PM
$PVLA - the stock has doubled since my post on 8.6. And it has gone past $60, 70, 75. Next milestone : hit $80 by Oct 31
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 3:52 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $74.85 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $11.70- $14.30 Scale out: $18.20-$23.40 Can Easily Capture: 60% ROI Blended DTE: 218 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 11:50 AM
Canaccord Genuity updates rating for Palvella Therapeutics ( $PVLA ) to Buy, target set at 66 → 90.
0 · Reply
Quantumup
Quantumup Oct. 9 at 10:59 AM
Canaccord Genuity⬆️ $PVLA $90 from $66 Canaccord Genuity said: PVLA recently announced the 3rd indication for QTORIN rapamycin: clinically significant angiokeratomas (conference call here, slides here). Like the drug's first two indications - mLM and CVM - clinically significant angiokeratoma is another rare, chronically debilitating skin disease with no approved therapies. PVLA estimates there are >50,000 diagnosed pts in the US - another large rare opportunity. The co will leverage the existing supply (already manufactured), the open IND, and current IP coverage for this new indication. We came away from the webcast+ additional diligence on our end encouraged by the potential of QTORIN rapa to treat this new indication given similarities with mLM and strong scientific rationale. As such, we are adding this new opportunity to our model, assuming peak sales of $860M at 20% POS. Initiation of the Phase 2 study for clinically significant angiokeratomas is anticipated in 2H26. Maintain BUY.
0 · Reply
JamesAnthonyR
JamesAnthonyR Oct. 8 at 8:43 PM
$PVLA the quietest 500% rally I have seen. Must be a lot of institutional accumulation.
1 · Reply
Avocado_smash
Avocado_smash Oct. 8 at 5:18 PM
$PVLA 🚀🚀🚀
0 · Reply
iQuicky
iQuicky Oct. 7 at 5:30 PM
$PVLA target price $85
0 · Reply
Latest News on PVLA
Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Sep 22, 2025, 7:30 AM EDT - 5 weeks ago

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM


LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $71.45 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $14.49- $17.71 Scale out: $22.54-$28.98 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
TalkMarkets
TalkMarkets Oct. 22 at 9:42 AM
Markets Are Choppy, But This One Zone Could Tell Us What’s Next For The S&P 500 $SPX $GH $BABA $PVLA https://talkmarkets.com/content/stocks--equities/markets-are-choppy-but-this-one-zone-could-tell-us-whats-next-for-the-sp-500?post=529717&userid=166882
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 18 at 5:46 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $73.14 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $11.70- $14.30 Scale out: $18.20-$23.40 Can Easily Capture: 60% ROI Blended DTE: 210 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
dadamoni
dadamoni Oct. 15 at 11:56 PM
$PVLA - the stock has doubled since my post on 8.6. And it has gone past $60, 70, 75. Next milestone : hit $80 by Oct 31
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 10 at 3:52 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $74.85 Contracts: $PVLA May 15, 2026 $75 Calls Scale in: $11.70- $14.30 Scale out: $18.20-$23.40 Can Easily Capture: 60% ROI Blended DTE: 218 Days | Join Elites here: https://liquidtheta.com/
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 11:50 AM
Canaccord Genuity updates rating for Palvella Therapeutics ( $PVLA ) to Buy, target set at 66 → 90.
0 · Reply
Quantumup
Quantumup Oct. 9 at 10:59 AM
Canaccord Genuity⬆️ $PVLA $90 from $66 Canaccord Genuity said: PVLA recently announced the 3rd indication for QTORIN rapamycin: clinically significant angiokeratomas (conference call here, slides here). Like the drug's first two indications - mLM and CVM - clinically significant angiokeratoma is another rare, chronically debilitating skin disease with no approved therapies. PVLA estimates there are >50,000 diagnosed pts in the US - another large rare opportunity. The co will leverage the existing supply (already manufactured), the open IND, and current IP coverage for this new indication. We came away from the webcast+ additional diligence on our end encouraged by the potential of QTORIN rapa to treat this new indication given similarities with mLM and strong scientific rationale. As such, we are adding this new opportunity to our model, assuming peak sales of $860M at 20% POS. Initiation of the Phase 2 study for clinically significant angiokeratomas is anticipated in 2H26. Maintain BUY.
0 · Reply
JamesAnthonyR
JamesAnthonyR Oct. 8 at 8:43 PM
$PVLA the quietest 500% rally I have seen. Must be a lot of institutional accumulation.
1 · Reply
Avocado_smash
Avocado_smash Oct. 8 at 5:18 PM
$PVLA 🚀🚀🚀
0 · Reply
iQuicky
iQuicky Oct. 7 at 5:30 PM
$PVLA target price $85
0 · Reply
Avocado_smash
Avocado_smash Oct. 7 at 5:14 PM
$PVLA 👇
0 · Reply
Avocado_smash
Avocado_smash Oct. 7 at 5:12 PM
$PVLA 🚀🚀
0 · Reply
Doozio
Doozio Oct. 7 at 2:41 PM
$PVLA 🐒🍌🧠⏰♾️
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 5 at 11:01 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $65.78 Contracts: $PVLA May 15, 2026 $65 Calls Scale in: $13.25- $16.20 Scale out: $20.61-$26.50 Can Easily Capture: 60% ROI Blended DTE: 224 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Doozio
Doozio Oct. 4 at 10:13 PM
$PVLA 🐒🍌🧠⏰♾️
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 3:08 PM
$PVLA Current Stock Price: $63.65 Contracts to trade: $65 PVLA Oct 17 2025 Call Entry: $0.50 Exit: $0.86 ROI: 72% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Quantumup
Quantumup Oct. 2 at 1:45 PM
Truist⬆️ $PVLA's PT to $80 from $56 and reiterated at a Buy rating after Tweaking its Model to Reflect Mgmt's Comments & Market Conditions Truist said in its note: We hosted a series of virtual investor meetings with Palvella management this week. Herein we outline some interesting tidbits and high level takeaways from the conversations which by and large centered in on: (1) conviction in MLM Ph 3 trial success/ rationale for trial design, (2) confidence in the MLM commercial opportunity, and (3) expectations for upcoming Ph 2 PoC data in CVM. We also updated our model to more accurately reflect PVLA's plans around a potential capital raise. After adjusting our model, our DCF yields an $80 PT (was $56). Of note, CVM and newly announced clinically significant angiokeratomas indications remain as potential upside to our ests.
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 6:21 PM
$PVLA: TRADE CALL orders came through 20 @ 13.20, Strike 65.0, Exp 5/15/2026, Premium $26,400, Sentiment BULLISH
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Sep. 26 at 12:23 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $PVLA Current Share Price: $58.87 Contracts: $PVLA February 20, 2026 $60 Calls Scale in: $9.34- $11.41 Scale out: $14.52-$18.68 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:38 AM
Chardan Capital updates rating for Palvella Therapeutics ( $PVLA ) to Buy, target set at 60 → 73.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 3:09 PM
HC Wainwright & Co. updates rating for Palvella Therapeutics ( $PVLA ) to Buy, target set at 75 → 95.
0 · Reply
Quantumup
Quantumup Sep. 24 at 7:17 PM
Oppenheimer⬆️ $PVLA to $90 from $85 and reiterated at an Outperform rating: Palvella hosted a webcast this morning demonstrating the unmet need and high market potential for Qtorin rapamycin in clinically significant angiokeratomas. Angiokeratomas likely affect millions of people in US, but those with clinically severe presentation are rare, affecting an estimated ~50K. These lesions have a lymphatic system root with VEGF/mTOR pathway stimulation, suggesting clear Qtorin rapamycin role. mTOR inhibition has also been validated with small real-world samples using lower-quality rapamycin formulations. KOLs see high unmet need, and have advocated for Qtorin's angiokeratoma development. Clinically severe presentations are frequently in sensitive areas including the genitals; these wouldn't be candidates for laser/surgical therapy. We are bullish on opportunity, and assign $100M for pipeline expectations. We believe initial Phase 2 data will unlock angiokeratoma value; PT to $90 from $85.
0 · Reply